Pulmonary Hypertension: State of the Art and Therapeutic Opportunities

肺动脉高压：最新技术和治疗机会

基本信息

批准号：
10682118
负责人：
TERRY L. SHEPPARD
金额：
$ 1.53万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10682118
关键词：
Address Aging Animal Model Area Basic Science Big Data Biology Biomedical Engineering Blood Vessels Career Choice Cell physiology Collaborations Creativeness Data Science Disease Educational workshop Fostering Future Genes Genetic Head Heart failure Heterogeneity Immune Inflammation Joints Knowledge Leadership Learning Light Lung Mentors Metabolism Methodology Mitochondria Modality Myocardial Natural regeneration New Agents New Mexico Outcome Pathology Pathway interactions Patients Penetrance Process Progressive Disease Pulmonary Circulation Pulmonary Hypertension Pulmonary Pathology Quality of life RNA Research Research Personnel Resistance Scientific Advances and Accomplishments Scientist Seasons Symbiosis System Therapeutic Therapeutic Intervention Translations Trees Untranslated RNA Variant Work career clinical practice design effective therapy efficacy evaluation epigenome epigenomics exosome health disparity improved innovation insight interest lung imaging meetings microbiome multidisciplinary next generation novel novel imaging technology novel strategies posters programs pulmonary arterial hypertension sex symposium

项目摘要

ABSTRACT Support is requested for a Keystone Symposia conference entitled Pulmonary Hypertension: State of the Art and Therapeutic Opportunities, organized by Drs. Marlene Rabinovitch and Kurt Stenmark. The conference will be held in Santa Fe, New Mexico from June 25 - 28, 2023. Pulmonary arterial hypertension is a progressive condition in which narrowing and obliteration of blood vessels results in elevated resistance to flow that culminates in heart failure. Current approved therapies improve survival and quality of life but new research approaches that tackle the complexities of pulmonary hypertension will allow us to identify, develop and pursue new agents that reverse disease. Therefore, this conference is designed to showcase the scientific advances in six areas that impact vascular and immune cell function: i) mitochondrial dynamics (ii) epigenomics and integrated omics (iii) aging and sex determinants (iv) genetics and data science (v) bioengineering and regeneration and (vi) inflammation. The conference program will cover the future of gene editing in pulmonary hypertension and heart failure. Speakers were invited with expertise in the above areas of interest, along with those who work on related aspects of pulmonary hypertension, in order to engage both seasoned and young investigators in a way that will catalyze innovative scientific approaches. Additionally, speakers will be challenged to relate their research to others in the field, to establish relationships and bridge gaps that will identify therapeutic possibilities beyond targeting one pathway or molecule. The program will also cover the pitfalls of current animal models and culture systems, in light of the complexities of the disease. There are also two workshops being planned. The first will highlight novel imaging technology in the field. The second is designed around the process of moving basic discovery to the patient. Finally, this conference will be held jointly with the Keystone Symposia meeting on Heart Failure. Attendees will share joint sessions, workshops, poster sessions, and mealtimes.

抽象的请求支持题为“肺动脉高压：最新技术”的 Keystone 研讨会和治疗机会，由博士组织。玛琳·拉宾诺维奇和库尔特·斯坦马克。会议将于2023年6月25日至28日在新墨西哥州圣达菲举行。肺动脉高压是一种进行性疾病，其中血管变窄和闭塞导致血流阻力升高，最终导致心力衰竭。目前批准的治疗方法有所改善生存和生活质量，但解决肺动脉高压复杂性的新研究方法将使我们能够识别、开发和寻求逆转疾病的新药物。因此，本次会议是旨在展示影响血管和免疫细胞功能的六个领域的科学进展：i) 线粒体动力学 (ii) 表观基因组学和综合组学 (iii) 衰老和性别决定因素 (iv) 遗传学和数据科学（v）生物工程和再生以及（vi）炎症。会议议程将涵盖基因编辑治疗肺动脉高压和心力衰竭的未来。邀请了具有以下专业知识的演讲者上述感兴趣的领域，以及那些从事肺动脉高压相关方面工作的人，以便以一种能够促进创新科学方法的方式吸引经验丰富的和年轻的研究人员。此外，演讲者将面临将他们的研究与该领域的其他人联系起来的挑战，以建立关系并弥合差距，确定除针对一种途径或分子之外的治疗可能性。这鉴于以下问题的复杂性，该计划还将涵盖当前动物模型和培养系统的缺陷这种疾病。还计划举办两个研讨会。第一个将重点介绍新型成像技术领域。第二个是围绕将基本发现转移给患者的过程而设计的。最后，这个会议将与心力衰竭 Keystone 研讨会联合举行。与会者将共同分享会议、研讨会、海报会议和用餐时间。